



## Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

### ESPS Peer-review Report

**Name of Journal:** World Journal of Nephrology

**ESPS Manuscript NO:** 5445

**Title:** PRIMARY FOCAL AND SEGMENTAL GLOMERULOSCLEROSIS AND suPAR: WHERE DO WE STAND AND WHERE ARE WE HEADING TO?

**Reviewer code:** 00503257

**Science editor:** Cui, Xue-Mei

**Date sent for review:** 2013-09-09 16:56

**Date reviewed:** 2013-09-12 14:52

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

### COMMENTS TO AUTHORS

This is an interesting and timely review paper. However, several points of writing style remain somewhat cloudy. Please use several subheadings, and then more clear and concise description should be encouraged. Also, to easily understand this important topic to the readers, English editing is needed.



# Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

## ESPS Peer-review Report

**Name of Journal:** World Journal of Nephrology

**ESPS Manuscript NO:** 5445

**Title:** PRIMARY FOCAL AND SEGMENTAL GLOMERULOSCLEROSIS AND suPAR: WHERE DO WE STAND AND WHERE ARE WE HEADING TO?

**Reviewer code:** 00503255

**Science editor:** Cui, Xue-Mei

**Date sent for review:** 2013-09-09 16:56

**Date reviewed:** 2013-09-13 09:46

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

Dr. Trimarchi reviewed latest developments regarding the pathophysiology of primary FSGS caused by suPAR and potential success in therapy. Title 1. The title has 18 words. It should be less than 12 words. 2. The running title less than 6 words should be provided Abstract 3. Line 9: "suPAR" should be changed to "soluble urokinase type plasminogen activator receptor (suPAR)" Text 4. No headings provided. Headings should be added such as "Introduction", "Biology of suPAR", "Summary", et cet. 5. Put reference numbers in square brackets in superscript at the end of citation content. 6. page 8, line: "FFSG" should be changed to "FSGS" References 7. PubMed citation numbers (PMID and DOI) should be provided to the reference list when available. 8. The reference number 48 and 49 are the same articles. Please delete no.49.